1.Effect of Euonymus alatus Extract on Antitumor Activity and Toxicity of Doxorubicin.
Yong MOON ; Byung Yong LEE ; Jeong Ho LEE
Korean Journal of Immunology 2000;22(4):299-309
No abstract available.
Doxorubicin*
;
Euonymus*
2.Effect of Adriamycin on Lipid Metabolismin Rats.
Chang Beom SHIN ; Sun Jun KIM ; Chan Unng JOO ; Dae Yeol LEE
Journal of the Korean Pediatric Society 1988;31(9):1133-1138
No abstract available.
Animals
;
Doxorubicin*
;
Rats*
3.Two cases of doxorubicin-induced dilated cardiomyopathy.
Jin Won PARK ; Kyeong Ah LEE ; Yong Woon PAIK ; Hyun Kee CHUNG ; Jae Sun PARK
Journal of the Korean Pediatric Society 1992;35(6):822-828
No abstract available.
Cardiomyopathy, Dilated*
;
Doxorubicin
4.Doxorubicin Cardiotoxicity: Response of Left Ventricular Ejection Fraction to Exercise and Incidence of Regional Wall Motion Abnormalities.
Jong Hoa BAE ; Markus SCHWAIGER ; Alexander LIN ; Mark MANDELKERN ; Heinrich R SCHELBERT
Korean Circulation Journal 1985;15(1):13-26
No abstract available.
Doxorubicin*
;
Incidence*
;
Stroke Volume*
5.FAM versus etoposide, adriamycin, and cisplatin:a random assignment trial in advanced gastric cancer.
Jung Ae LEE ; Jung Soo YOON ; Sung Hyun YANG ; Si Young KIM ; Dae Suk HUH ; Young Joo BANG ; Kyung Sam CHO ; No Kyung KIM
Journal of the Korean Cancer Association 1993;25(4):461-467
No abstract available.
Doxorubicin*
;
Etoposide*
;
Stomach Neoplasms*
6.The Effect of Adriamycin on Ionic Currents in Single Cardiac Myocytes of the Rabbit.
Journal of the Korean Pediatric Society 1995;38(8):1093-1106
No abstract available.
Doxorubicin*
;
Myocytes, Cardiac*
7.Characterization of purified coconut oil bodies as an encapsulating agent for Doxorubicin and Paclitaxel
Pamela T. Aliman ; Ronina Franne N. Cada ; Mark Kevin P. Devanadera ; Alexis M. Labrador ; Myla R. Santiago-Bautista
Acta Medica Philippina 2021;55(4):442-450
Introduction:
Doxorubicin (DOX) and paclitaxel (PTX) are both widely used anticancer drugs with a broad spectrum of antitumor activity, commonly against breast, ovarian, and lung cancers. Currently, these drugs are commercially available in liposomal formulations for their use in chemotherapy. This study generally proposed coconut oil bodies (COB) obtained from Cocos nucifera L. as an alternative carrier for DOX and PTX rather than the currently used liposome.
Objectives:
This study aimed to compare standard liposome and coconut oil bodies as drug carriers in terms of their microencapsulation efficiencies, lipid profiles, in vitro drug release and stability, as well as their cholesterol levels.
Methods:
Coconut oil bodies (COB) were isolated and purified from Cocos nucifera L. by modified sucrose
gradient method followed by microencapsulation of standard drugs (doxorubicin and paclitaxel) through selfassembly and freeze-thaw method. The two standard drugs were encapsulated using COB and standard liposome. Encapsulation efficiency of both materials were determined. Lipid profiles of both encapsulating materials were analyzed by Fourier-transform infrared spectroscopy, gas chromatography-flame ionization detector, and cholesterol level determination. In vitro drug release and pH stability of both encapsulated drugs were analyzed.
Results:
Doxorubicin (DOX) and paclitaxel (PTX) were successfully incorporated in COB. Lauric acid was mainly
abundant in COB and was able to lower cholesterol levels (5 mg/dL). COB incorporated with DOX and PTX
showed stability at acidic and neutral pH. Drug release profile showed a rapid outburst within 3 hours compared to liposome encapsulated DOX and PTX.
Conclusion
Our study showed the encouraging potentials of using COB as wall materials that will make them
attractive candidates for the formulation of pharmaceuticals for optimized drug delivery of cancer chemotherapeutics DOX and PTX
Liposomes
;
Doxorubicin
;
Paclitaxel
8.Myocardial Protective Effect of Cardioxane for the Myocardial Damage due to Doxorubicin.
Hee Ju PARK ; Jai Min OH ; Sung Hoon KIM ; Chang Hoon LEE ; Sang Sik KIM
Journal of the Korean Pediatric Society 2003;46(9):876-882
PURPOSE: To find out the myocardial protective effect of cardioxane for the myocardial damage by doxorubicin. METHODS: Using Eighteen rabbits(2.0-3.2 kg), doxorubicin(30 mg/m2) was injected intravenously once a week in group I(12 rabbits) and cardioxane(600 mg/m2) was injected at 20-30 minutes before doxorubicin administration in group II(6 rabbits). After this, we operated on the rabbits when the total cumulative dose of doxorubicin was reached at 210, 240, 270 and 300 mg/m2 and observed the degree of myocardial damage with light and electronic microscope. RESULTS: In group I, rabbits with less than 210 mg/m2 of total cumulative dose of doxorubicin, there was no definite myocardial damage but with 240 mg/m2, focal degenerative change was observed and with 300 mg/m2, severe degenerative change was detected with light microscopic examination. With electronic microscope, rabbits with less than 180 mg/m2 of total cumulative dose of doxorubicin in group I, there was no evidence of myocardial damage. In 210 mg/m2, focal degenerative change was detected. With 240 mg/m2, degenerative change was much more advanced and with 300 mg/m2, severe degenerative change was detected. In group II, no definite myocardial damage was observed even though the total cumulative dose of doxorubicin reached 300 mg/m2, but with 360 mg/m2, there was a focal area where myocardial fibers were somewhat decreased, but it's difficult to say whether these decrement were due to adriamycin in the electronic microscopic examination. CONCLUSION: Cardioxane have a good protective effect for the doxorubicin induced cardiomyopathy and it will be used safely in pediatric cancer patients.
Cardiomyopathies
;
Dexrazoxane*
;
Doxorubicin*
;
Humans
;
Rabbits
9.Effects of combination timing of recombinant human interferon-?and adriamycin on cytotoxicity to human stomach cancer cells.
Weon Seon HONG ; Young Sook SON ; Chang Min KIM ; Yoon Koo KANG ; Choon Taek LEE ; You Cheoul KIM ; Young Hyuck IM ; Hyeon Seok NAM ; Jhin Oh LEE ; Tae Woong KANG
Korean Journal of Immunology 1993;15(2):263-269
No abstract available.
Doxorubicin*
;
Humans*
;
Stomach Neoplasms*
;
Stomach*
10.Effect of the Local Doxorubicin Injection on the Extraocular Muscle.
Nam Yeo KANG ; Ho Min JEON ; Soo Chul PARK ; Chan PARK
Journal of the Korean Ophthalmological Society 1998;39(2):406-413
To investigate the chemomyectomy effect of doxorubicin on extraocular muscle, we injected 0.05ml doxorubicin into right superior rectus muscle for the experimental group and 0.05ml balanced salt solution into left superior rectus muscle for the control group of 12 rabbits. The gross and histologic examinations were done at 1, 2, 4 and 8 weeks after the injection. The results were as follows; 1. On gross examination, thickness of muscle mass at injection site was decreased with the time in the experimental group, and neither conjunctival adhesion and symblepharon nor scleral necrosis was found in both groups. 2. On microscopic examination, the degree of muscle fragmentation and necrosis was increased with the lapse of time in the experimental group. But there was no observable change with the lapse of time in the control group. These results suggested that doxorubicin was such a selective myotoxin to extraocular muscles that it could be used for nonsurgical treatment of chronic paralytic and restricted form of strabismus.
Doxorubicin*
;
Muscles
;
Necrosis
;
Rabbits
;
Strabismus